Lavipharm Statistics

Total Valuation

Lavipharm has a market cap or net worth of EUR 135.63 million. The enterprise value is 158.28 million.

Market Cap	135.63M
Enterprise Value	158.28M

Important Dates

The last earnings date was Monday, March 24, 2025.

Earnings Date	Mar 24, 2025
Ex-Dividend Date	n/a

Share Statistics

Lavipharm has 168.69 million shares outstanding.

Current Share Class	n/a
Shares Outstanding	168.69M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	0.51%
Owned by Institutions (%)	3.39%
Float	64.01M

Valuation Ratios

The trailing PE ratio is 15.10.

PE Ratio	15.10
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	17.63
EV / Sales	2.99
EV / EBITDA	17.26
EV / EBIT	28.58
EV / FCF	n/a

Financial Position

Current Ratio	n/a
Quick Ratio	n/a
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	2.86

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	n/a
Revenue Per Employee	176,490
Profits Per Employee	29,930
Employee Count	307
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -9.26% in the last 52 weeks. The beta is 1.22, so Lavipharm's price volatility has been higher than the market average.

Beta (5Y)	1.22
52-Week Price Change	-9.26%
50-Day Moving Average	0.82
200-Day Moving Average	0.81
Relative Strength Index (RSI)	46.62
Average Volume (20 Days)	197,945

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Lavipharm had revenue of EUR 52.95 million and earned 8.98 million in profits.

Revenue	52.95M
Gross Profit	25.08M
Operating Income	5.54M
Pretax Income	3.60M
Net Income	8.98M
EBITDA	9.17M
EBIT	5.54M
Earnings Per Share (EPS)	n/a

Full Income Statement

Balance Sheet

Cash & Cash Equivalents	n/a
Total Debt	n/a
Net Cash	n/a
Net Cash Per Share	n/a
Equity (Book Value)	n/a
Book Value Per Share	n/a
Working Capital	n/a

Full Balance Sheet

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 47.37%, with operating and profit margins of 10.46% and 16.96%.

Gross Margin	47.37%
Operating Margin	10.46%
Pretax Margin	6.81%
Profit Margin	16.96%
EBITDA Margin	17.32%
EBIT Margin	10.46%
FCF Margin	n/a

Dividends & Yields

Lavipharm does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	6.62%
FCF Yield	n/a

Stock Splits

The last stock split was on August 1, 2022. It was a reverse split with a ratio of 0.3333333333.

Last Split Date	Aug 1, 2022
Split Type	Reverse
Split Ratio	0.3333333333

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a